This Is How You Do Value-Based Care
Working with Regeneron and Sanofi, Express Scripts will be the first to directly deliver drug-specific savings to patients, making PCSK9 therapy more affordable and more accessible.
Today we announced a new agreement with Regeneron Pharmaceuticals and Sanofi, makers of the PCSK9 inhibitor Praluent® (alirocumab) Injection, that will greatly improve the affordability and accessibility of this medication for patients whose plans are enrolled in our Cholesterol Care Value Program, part of our SafeGuardRxSM suite of solutions.
